Navigation Links
Media Alert: Discovery Labs to Hold Conference Call to Discuss FDA Approval of SURFAXIN® (lucinactant)
Date:3/7/2012

WARRINGTON, Pa., March 7, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, will hold a conference call for investors today at 10 a.m. EST to discuss its March 6th announcement that SURFAXIN (lucinactant) has been approved by the FDA for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS.  SURFAXIN is the first FDA-approved synthetic, peptide-containing surfactant.

The call-in number is (877) 215-0093. The international call in number is (706) 679-3237.  The passcode is 58400332. This audio webcast will be available through a live broadcast on the Internet at http://us.meeting-stream.com/discoverylaboratories_030212 and www.discoverylabs.com. The replay number to hear the conference call is (855) 859-2056 or (404) 537-3406 using the same conference call password listed above.

IMPORTANT SAFETY INFORMATION

SURFAXIN (lucinactant intratracheal suspension) is intended for intratracheal use only.  The administration of exogenous surfactants, including SURFAXIN, can rapidly affect oxygenation and lung compliance.  SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly supervised clinical setting. Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.

Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption.  During SURFAXIN administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant's clinical condition assessed and stabilized. SURFAXIN is not indicated for use in acute respiratory distress syndrome (ARDS).

For more information about SURFAXIN, please visit www.surfaxin.com.


'/>"/>
SOURCE Discovery Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
2. Hospital to Hold MRSA Briefing for Media and Community Leaders
3. Superbug Outbreak Calls for Immediate Increased Attention on Infection Control
4. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
5. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
6. Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
8. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
9. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
10. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
11. New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016   Arena Pharmaceuticals, Inc. ... it has completed enrollment in the ralinepag phase 2 ... targeting the prostacyclin pathway for the treatment of pulmonary ... at sites globally. "This marks an important ... of our strategic focus on our pipeline," said ...
(Date:12/7/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) has launched Diplomat Specialty Infusion Group, ... Professional, BioRx, MedPro Rx, and XAS Infusion Suites. To ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... we continue to build on the work we have done, we ...
(Date:12/7/2016)... 2016   Rx Savings Solutions has partnered with ... its Public Employees Insurance Agency (PEIA) to offer more than ... healthcare software, ultimately saving money on their prescriptions. ... members with access to our software that will alert them ... therapy can be found," says Michael Rea , founder ...
Breaking Medicine Technology:
(Date:12/7/2016)... Norwalk, CT (PRWEB) , ... December 07, 2016 ... ... the Integrated Infertility and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut ... which now has a team of three acupuncturists to help patients realize their ...
(Date:12/7/2016)... ... ... With God: Inspirational Lessons from My Life's Journey”: a sometimes serious, sometimes humorous ... in their lives. “Walking With God: Inspirational Lessons from My Life's Journey” is the ... , Sanford says, “I enjoy sharing the true stories in my book as examples ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... annual Business Architecture Innovation Summit in Reston, VA on March 21-22, 2017. This ... share a range of experiences from a cross-section of industries such as financial ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Hacking into my medical ... described him as 'a genius.'" Thus begins "Margaret in Berlin," Book Twelve in the ... by Wyston Books, Inc. These novels narrate the lives of a poor ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men with gum disease ... of serious health problems, such as cardiovascular illness, according to research cited in ... Hills Periodontics & Dental Implant Center notes that the correlation between periodontal disease ...
Breaking Medicine News(10 mins):